Biosimilar Inspection Modernization Act of 2025
This bill seeks to modernize Food and Drug Administration inspections of establishments that manufacture or process biosimilar biological products. It requires a public meeting and report on mutual recognition agreements, updates inspection tools to support risk-based and remote assessments, and requires a strategic plan to address domestic inspection challenges.